dacarbazine has been researched along with Digestive System Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T | 1 |
| Claringbold, PG; Kesavan, M; Turner, JH | 1 |
| Couvelard, A; Faivre, S; Hammel, P; Hentic, O; Larroque, B; Lévy, P; Maire, F; Raymond, E; Ruszniewski, P; Yapur, L; Zappa, M | 1 |
| Dugan, M; Gerson, SL; Izbicka, E; Raymond, E; Soda, H; Von Hoff, DD | 1 |
1 trial(s) available for dacarbazine and Digestive System Neoplasms
| Article | Year |
|---|---|
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2014 |
3 other study(ies) available for dacarbazine and Digestive System Neoplasms
| Article | Year |
|---|---|
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Digestive System Neoplasms; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Propensity Score; Temozolomide | 2019 |
Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Digestive System Neoplasms; Disease Progression; Endocrine Gland Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Temozolomide; Time Factors; Treatment Outcome | 2009 |
Activity of temozolomide against human tumor colony-forming units.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cell Division; Dacarbazine; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Hematologic Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplastic Stem Cells; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Urogenital Neoplasms | 1997 |